for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ANI Pharmaceuticals Inc

ANIP.OQ

Latest Trade

61.09USD

Change

-0.87(-1.40%)

Volume

23,754

Today's Range

60.72

 - 

61.88

52 Week Range

39.83

 - 

86.67

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
61.96
Open
61.88
Volume
23,754
3M AVG Volume
3.97
Today's High
61.88
Today's Low
60.72
52 Week High
86.67
52 Week Low
39.83
Shares Out (MIL)
12.09
Market Cap (MIL)
749.16
Forward P/E
12.05
Dividend (Yield %)
--

Latest Developments

More

Ani Pharmaceuticals Reports Q3 EPS Non-GAAP $1.23

Ani Pharmaceuticals Announces The Launch Of Ani Global Source

Ani Announces Positive Clinical Results From Cortrophin Gel Cortisol Response Study

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Industry

Biotechnology & Drugs

Contact Info

210 W Main St

+1.218.6343500

http://www.anipharmaceuticals.com/

Executive Leadership

Robert E. Brown

Independent Chairman of the Board

Arthur S. Przybyl

President, Chief Executive Officer, Director

Stephen P. Carey

Chief Financial Officer, Vice President - Finance

Robert W. Schrepfer

Senior Vice President -New Business Development and Specialty Sales

James G. Marken

Senior Vice President-Operations and Product Development

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.2K

2018

0.2K

2019(E)

0.2K
EPS (USD)

2016

3.780

2017

3.910

2018

5.070

2019(E)

5.143
Price To Earnings (TTM)
46.27
Price To Sales (TTM)
3.47
Price To Book (MRQ)
3.51
Price To Cash Flow (TTM)
12.43
Total Debt To Equity (MRQ)
87.56
LT Debt To Equity (MRQ)
30.44
Return on Investment (TTM)
4.82
Return on Equity (TTM)
3.65

Latest News

Latest News

BRIEF-ANI Pharmaceuticals Reports Q1 GAAP Earnings Per Share $0.19

* ANI PHARMACEUTICALS REPORTS FIRST QUARTER 2018 RESULTS AND REAFFIRMS GUIDANCE

BRIEF-Ani Pharmaceuticals To Acquire Generic Products And Assets From Amneal/Impax

* ANI PHARMACEUTICALS SIGNS DEFINITIVE AGREEMENTS TO ACQUIRE GENERIC PRODUCTS AND ASSETS FROM AMNEAL/IMPAX

BRIEF-ANI Pharmaceuticals Announces Approval Of Morphine Sulfate Oral Solution

* ANI PHARMACEUTICALS ANNOUNCES APPROVAL OF MORPHINE SULFATE ORAL SOLUTION

BRIEF-ANI Acquires 23 ANDAs From IDT Australia

ANI Pharmaceuticals Inc - Deal For $2.6 Mln And A Limited Single :

BRIEF-IDT Australia To Divest Selection Of Generic Product Portfolio To Ani Pharmaceuticals

* TO DIVEST A SELECTION OF ITS GENERIC PRODUCT PORTFOLIO TO ANI PHARMACEUTICALS INC

BRIEF-ANI Pharmaceuticals Q4 Adjusted Non-GAAP Earnings Per Share $1.08

* ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR RESULTS, REPORTS FOURTH QUARTER 2017 RESULTS, AND PROVIDES 2018 GUIDANCE

BRIEF-Ani Pharmaceuticals Enters Five-Year $125 Mln Senior Secured Credit Facility With Citizens Bank

* ANI PHARMACEUTICALS ENTERS FIVE-YEAR $125 MILLION SENIOR SECURED CREDIT FACILITY WITH CITIZENS BANK

BRIEF-Ani Pharmaceuticals Acquires Four NDAs From AstraZeneca For $46.5 Mln

* ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION

BRIEF-ANI Pharmaceuticals Q3 gaap earnings per share $0.40

* ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance

BRIEF-ANI Pharmaceuticals announces launch of Oxycodone Hydrochloride oral solution

* ANI Pharmaceuticals Inc announces approval and launch of Oxycodone Hydrochloride oral solution, 100 mg/5ml

BRIEF-Ani pharmaceuticals reports Q2 adj. earnings of $0.98/shr

* Ani Pharmaceuticals reports record second quarter and year-to-date 2017 results and reaffirms guidance

BRIEF-ANI Pharmaceuticals announced launch of diphenoxylate hcl and atropine sulfate tablets

* Ani Pharmaceuticals Inc - announced launch of diphenoxylate hcl and atropine sulfate tablets, 2.5mg/0.025mg Source text for Eikon: Further company coverage:

BRIEF-ANI Pharmaceuticals files for mixed shelf of up to $350.0 million

* Files for mixed shelf of up to $350.0 million Source text: (http://bit.ly/2rokUdK) Further company coverage:

BRIEF-ANI Pharma announces launch of Pindolol tablets

* Ani pharmaceuticals inc - launch of pindolol tablets, 5mg and 10mg, which is used in treatment of hypertension Source text for Eikon: Further company coverage:

BRIEF-Ani Pharmaceuticals reports Q1 GAAP earnings per share $0.10

* Ani Pharmaceuticals reports first quarter results and year-to-date 2017 highlights and reaffirms guidance

BRIEF-ANI Pharmaceuticals launch of Indapamide tablets

* ANI Pharmaceuticals -launch of Indapamide tablets, 1.25mg and 2.5mg, used in treatment of hypertension & swelling associated with congestive heart failure Source text for Eikon: Further company coverage:

BRIEF-ANI Pharmaceuticals reports Q4 loss per share $0.09

* Ani pharmaceuticals reports full year 2016 results and fourth quarter results and provides 2017 guidance

BRIEF-Ani Pharma acquires Inderal XL and Innopran XL

* Ani pharmaceuticals inc - acquisitions were funded through a combination of cash and debt

BRIEF-Ani Pharmaceuticals pays about $20 mln in consideration for acquisition of Cranford assets

* Ani Pharmaceuticals Inc - in consideration for acquisition of Cranford assets, company paid a purchase price of approximately $20 million - SEC filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up